Global Oncology Academy - Global Oncology Academy

Global Oncology Academy

Global Oncology Academy

Enhance your practice with CME
and tools that focus on the management
and treatment of patients with cancer.

Popular

Assessing and Interpreting pCR in Perioperative NSCLC
Assessing and Interpreting pCR in Perioperative NSCLC
Project Oncology®
Assessing and Interpreting pCR in Perioperative NSCLC
Steve Jackson, PharmD; Alexander Spira, MD, PhD, FACP
- Steve Jackson, PharmD
- Alexander Spira, MD, PhD, FACP
Decoding epNECs: Diagnostic Challenges and Emerging Strategies
Decoding epNECs: Diagnostic Challenges and Emerging Strategies
Project Oncology®
Decoding epNECs: Diagnostic Challenges and Emerging Strategies
Brian P. McDonough, MD, FAAFP; Andrew E. Hendifar, MD
- Brian P. McDonough, MD, FAAFP
- Andrew E. Hendifar, MD
DESTINY-Breast05 Findings Lead to New Indication for Trastuzumab Deruxtecan as Adjuvant Treatment for Residual Invasive Disease
DESTINY-Breast05 Findings Lead to New Indication for Trastuzumab Deruxtecan as Adjuvant Treatment for Residual Invasive Disease
Oncology and Hematology
DESTINY-Breast05 Findings Lead to New Indication for Trastuzumab Deruxtecan as Adjuvant Treatment for Residual Invasive Disease
Sara A. Hurvitz, MD, FACP
- Sara A. Hurvitz, MD, FACP
Key Differences in Pulmonary and Extrapulmonary NEC Management
Key Differences in Pulmonary and Extrapulmonary NEC Management
Project Oncology®
Key Differences in Pulmonary and Extrapulmonary NEC Management
Alexandria May, PharmD, BCPS; Lowell B. Anthony, MD, FACP
- Alexandria May, PharmD, BCPS
- Lowell B. Anthony, MD, FACP
Evolving epNEC Care: From Default Regimens to Precision-Driven Strategies
Evolving epNEC Care: From Default Regimens to Precision-Driven Strategies
Project Oncology®
Evolving epNEC Care: From Default Regimens to Precision-Driven Strategies
Alexandria May, PharmD, BCPS; Chandrikha Chandrasekharan, MBBS
- Alexandria May, PharmD, BCPS
- Chandrikha Chandrasekharan, MBBS
Advancing Management of Extrapulmonary NEC: The Emerging Role of DLL3
Advancing Management of Extrapulmonary NEC: The Emerging Role of DLL3
Project Oncology®
Advancing Management of Extrapulmonary NEC: The Emerging Role of DLL3
Charles Turck, PharmD, BCPS, BCCCP; Rohit Thummalapalli, MD
- Charles Turck, PharmD, BCPS, BCCCP
- Rohit Thummalapalli, MD
TROPION-Breast02: Evidence for the Approval of Datopotamab Deruxtecan for Patients With mTNBC Ineligible for Immunotherapy
TROPION-Breast02: Evidence for the Approval of Datopotamab Deruxtecan for Patients With mTNBC Ineligible for Immunotherapy
Oncology and Hematology
TROPION-Breast02: Evidence for the Approval of Datopotamab Deruxtecan for Patients With mTNBC Ineligible for Immunotherapy
Tiffany Traina, MD, FASCO
- Tiffany Traina, MD, FASCO
Optimizing Treatment Intensity in Early-Stage TNBC
Optimizing Treatment Intensity in Early-Stage TNBC
Project Oncology®
Optimizing Treatment Intensity in Early-Stage TNBC
Roberto Leon-Ferre, MD
- Roberto Leon-Ferre, MD

Medical News

Medical News
Postoperative Nivolumab Does Not Improve DFS in Resected NSCLC
06/08/2026
Read more
Medical News
Trastuzumab Deruxtecan Plus Pertuzumab in HER2-Positive Metastatic Breast Cancer
06/08/2026
Read more
Medical News
Same-Session LITT Plus Biopsy in Unresectable Glioblastoma
06/08/2026
Read more
Medical News
COLOR III Short-Term Outcomes: taTME vs Laparoscopic TME
06/05/2026
Read more

CME/CE

NEW EPISODE
Ongoing Trials in Oral Targeted Strategies in Breast Cancer
Ongoing Trials in Oral Targeted Strategies in Breast Cancer
MinuteCE®
Ongoing Trials in Oral Targeted Strategies in Breast Cancer
Aditya Bardia, MD, MPH, FASCO
0.50 program credits
- Aditya Bardia, MD, MPH, FASCO
0.50 program credits
MinuteCE®
Rapid Data Pulses From ASCO 2026: Emerging Data on Oral Targeted Strategies in Breast Cancer
Aditya Bardia, MD, MPH, FASCO; Erica L. Mayer, MD, MPH
0.50 credits 3 episodes
- Aditya Bardia, MD, MPH, FASCO
- Erica L. Mayer, MD, MPH
0.50 credits 3 episodes
Before the Scalpel: Identifying Candidates for Perioperative Immunotherapy
Before the Scalpel: Identifying Candidates for Perioperative Immunotherapy
MinuteCE®
Before the Scalpel: Identifying Candidates for Perioperative Immunotherapy
Adam J. Luginbuhl, MD
0.50 program credits
- Adam J. Luginbuhl, MD
0.50 program credits
Choosing the Path Forward: A Real-World Dialogue on Perioperative Immunotherapy
Choosing the Path Forward: A Real-World Dialogue on Perioperative Immunotherapy
MinuteCE®
Choosing the Path Forward: A Real-World Dialogue on Perioperative Immunotherapy
Adam J. Luginbuhl, MD
0.50 program credits
- Adam J. Luginbuhl, MD
0.50 program credits

Clinical Practice

NEW EPISODE
ELEVATE: Elacestrant Plus Capivasertib in Advanced Breast Cancer
ELEVATE: Elacestrant Plus Capivasertib in Advanced Breast Cancer
MinuteCE®
ELEVATE: Elacestrant Plus Capivasertib in Advanced Breast Cancer
Aditya Bardia, MD, MPH, FASCO
0.50 program credits
- Aditya Bardia, MD, MPH, FASCO
0.50 program credits
NEW EPISODE
SERENA-6: Acting on ESR1 Mutations in Advanced Breast Cancer
SERENA-6: Acting on ESR1 Mutations in Advanced Breast Cancer
MinuteCE®
SERENA-6: Acting on ESR1 Mutations in Advanced Breast Cancer
Erica L. Mayer, MD, MPH
0.50 program credits
- Erica L. Mayer, MD, MPH
0.50 program credits
Navigating Classification of High-Grade Neuroendocrine Neoplasms
Navigating Classification of High-Grade Neuroendocrine Neoplasms
Project Oncology®
Navigating Classification of High-Grade Neuroendocrine Neoplasms
Charles Turck, PharmD, BCPS, BCCCP; Rohit Thummalapalli, MD
- Charles Turck, PharmD, BCPS, BCCCP
- Rohit Thummalapalli, MD
DESTINY-Breast11: Trastuzumab Deruxtecan Followed by THP Yields New Indication in the Neoadjuvant Setting.
DESTINY-Breast11: Trastuzumab Deruxtecan Followed by THP Yields New Indication in the Neoadjuvant Setting.
Oncology and Hematology
DESTINY-Breast11: Trastuzumab Deruxtecan Followed by THP Yields New Indication in the Neoadjuvant Setting.
Sara A. Hurvitz, MD, FACP
- Sara A. Hurvitz, MD, FACP

Programs

MinuteCE®
Talking Through Treatment: Patient–Clinician Dialogue on Perioperative Immunotherapy in Locally Advanced HNSCC
Jennifer Johnson, MD, PhD; Adam J. Luginbuhl, MD
0.50 credits 5 episodes
- Jennifer Johnson, MD, PhD
- Adam J. Luginbuhl, MD
0.50 credits 5 episodes
Turning Evidence Into Action: Applying Perioperative Data to Real-World Practice
Turning Evidence Into Action: Applying Perioperative Data to Real-World Practice
MinuteCE®
Turning Evidence Into Action: Applying Perioperative Data to Real-World Practice
Jennifer Johnson, MD, PhD
0.50 program credits
- Jennifer Johnson, MD, PhD
0.50 program credits
Implementing Lifestyle Medicine in Breast Cancer Survivorship Care
Implementing Lifestyle Medicine in Breast Cancer Survivorship Care
Project Oncology®
Implementing Lifestyle Medicine in Breast Cancer Survivorship Care
Amy Comander, MD
- Amy Comander, MD
DPYD Testing Before Fluoropyrimidine Therapy: Benefits, Risks, and Guidance
DPYD Testing Before Fluoropyrimidine Therapy: Benefits, Risks, and Guidance
Project Oncology®
DPYD Testing Before Fluoropyrimidine Therapy: Benefits, Risks, and Guidance
Daniel Hertz, PhD, PharmD
- Daniel Hertz, PhD, PharmD